SYRE — Spyre Therapeutics, Inc.

Summary of Aeglea BioTherapeutics Q4 2018 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $14.9 million for Q4 2018, compared to a net loss of $6.5 million in Q4 2017.
• Loss per Share: $0.62 in Q4 2018 versus $0.39 in Q4 2017.
• Revenue: $1.5 million in grant revenue for Q4 2018, primarily from a $19.8 million cancer research grant.
• Cash Position: Pro forma cash of approximately $139 million as of December 31, 2018, following a $69 million financing in February 2019, expected to fund operations through the PEACE trial readout in Q1 2021.
• Operating Expenses: Increased R&D expenses to $11.8 million in Q4 2018 from $5.8 million in Q4 2017, reflecting investment in clinical development.

2. Strategic Updates and Business Highlights

• Significant progress in clinical programs for pegzilarginase in Arginase 1 Deficiency and oncology.
• Initiated IND-enabling studies for new pipeline programs targeting cystinuria and homocystinuria.
• Completed enrollment in Phase 1/2 clinical trials for pegzilarginase and reported interim data at ESMO.
• Launched a pivotal Phase 3 PEACE trial for pegzilarginase, with the first patient expected to be dosed in Q2 2019.

3. Forward Guidance and Outlook

• Anticipated quarterly cash burn of $12 million to $15 million, with a higher burn of $15 million to $17 million expected in Q1 2019 due to ramped-up development activities.
• Guidance for IND filings: homocystinuria in Q1 2020 and cystinuria in H2 2020.
• Expect top-line data from the Phase 1b combination trial with KEYTRUDA in Small Cell Lung Cancer in the first half of 2020.

4. Bad News, Challenges, or Points of Concern

• No observed objective responses in the Small Cell Lung Cancer cohort during the Phase 1 trial, raising questions about the efficacy of pegzilarginase in this indication.
• The company faces challenges in establishing the prevalence of Arginase 1 Deficiency, as it may be underrepresented in the patient population.
• Increased operating expenses may impact cash runway if clinical trials do not yield expected results.

5. Notable Q&A Insights

• Management expressed confidence in the clinical benefits of pegzilarginase, emphasizing its transformative potential for patients with Arginase 1 Deficiency.
• Discussions regarding the potential for a Pediatric Review Voucher were clarified, indicating eligibility upon drug approval.
• The rationale for selecting specific cancer types in the Basket trial was based on the dependency of those tumors on extracellular arginine, with a focus on ASS1 expression levels.
• Management highlighted the importance of plasma arginine control and its correlation with clinical outcomes, which could influence pricing strategies for the drug.

Overall, Aeglea BioTherapeutics demonstrated a strong commitment to advancing its clinical programs while navigating financial challenges and uncertainties in trial outcomes.